Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
|Technology Name |
(St. Jude Reference #)
|Cyclin C variants and diagnostic and therapeutic uses thereof (SJ-99-0011)|
|Description||This invention describes a truncated cyclin C protein that acts as an endogenous cyclin C inhibitor which can be used to develop diagnostic and therapeutic treatments for a number of different cancers. The level of truncated cyclin C expression in tumors can be modulated by either increasing (through the use of gene therapy vectors) or decreasing (using anti-sense RNA technology) the amount of truncated cyclin C protein within the cancerous cells. In addition, this invention could also be developed into a preventive treatment in precancerous lesions that are known to progress into cancer, such as dysplasias of the cervix, esophagus and lung, by manipulating the level of truncated cyclin C expression.|
|Keywords||Cyclin C, cancer therapeutic and diagnostic, cell cycle regulation|
|Granted Patents or Published Applications||U.S. Patent Nos. 6,075,123; 6,306,648|
|Related Scientific References|| |
Kidd, et al., “Regulated expression of a cell division control-related protein kinase during Development”, Cell Growth & Differ. 2:85-93 (1991); Lahti, et al.,
“Alterations in the PITSLRE protein kinase gene complex on chromosome1p36 in childhood neuroblastoma”, Nature Genetics 7:370-375 (1994);
Lahti, et al., “PITSLRE protein kinase activity is associated with apoptosis”, Mol. Cell. Biol. 15:1-11 (1995).
|Licensing Opportunities||We are currently seeking licensing opportunities in all fields for the development of this technology.|
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: June 2006